Nyxoah (NASDAQ:NYXH) Announces Earnings Results

Nyxoah (NASDAQ:NYXH) issued its quarterly earnings results on Tuesday. The company reported ($0.43) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.11, FiscalAI reports. Nyxoah had a negative return on equity of 139.18% and a negative net margin of 884.69%.The company had revenue of $7.38 million for the quarter, compared to the consensus estimate of $7.05 million.

Nyxoah Stock Down 7.8%

NYXH traded down $0.26 during trading on Tuesday, hitting $3.07. The company had a trading volume of 24,489 shares, compared to its average volume of 48,456. The company has a market cap of $118.99 million, a PE ratio of -1.15 and a beta of 1.56. The business has a 50-day moving average of $3.25 and a 200-day moving average of $4.28. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.25 and a quick ratio of 1.16. Nyxoah has a 1-year low of $2.76 and a 1-year high of $8.64.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on NYXH shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $11.00 price target on shares of Nyxoah in a research note on Monday, March 23rd. Stifel Nicolaus reaffirmed a “hold” rating and issued a $5.00 price target (down from $8.00) on shares of Nyxoah in a research note on Tuesday. Finally, Weiss Ratings lowered Nyxoah from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, April 22nd. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $8.33.

Institutional Trading of Nyxoah

Several institutional investors have recently added to or reduced their stakes in the stock. Heights Capital Management Inc. bought a new stake in Nyxoah in the fourth quarter valued at about $3,575,000. Shay Capital LLC bought a new position in Nyxoah during the 2nd quarter worth approximately $374,000. Citadel Advisors LLC bought a new stake in shares of Nyxoah in the 3rd quarter valued at approximately $98,000. Bank of America Corp DE increased its holdings in shares of Nyxoah by 152.7% in the 3rd quarter. Bank of America Corp DE now owns 19,878 shares of the company’s stock valued at $91,000 after acquiring an additional 12,012 shares during the last quarter. Finally, Deutsche Bank AG increased its holdings in shares of Nyxoah by 40.0% in the 4th quarter. Deutsche Bank AG now owns 35,000 shares of the company’s stock valued at $161,000 after acquiring an additional 10,000 shares during the last quarter.

Nyxoah Company Profile

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep?disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.